Pfizer Strengthens Immuno-Oncology Portfolio with $200 Million Investment in Chinese Startup
By Ruchi Jhonsa, Ph.D. Even though Pfizer holds a solid reputation in oncology, it lags in the immunotherapy sector with just one immune-oncology drug in the market. Bavencio, an anti-PD-1 …
Read More